Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary Remove Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Summaries of opinion Remove Summaries of opinion filter Withdrawn applications Remove Withdrawn applications filter Paediatric investigation plans Remove Paediatric investigation plans filter Orphan designations Remove Orphan designations filter Referrals (4) Apply Referrals filter Direct healthcare professional communication (11) Apply Direct healthcare professional communication filter

Product number

Patient safety

Yes (3) Apply Yes filter

Authorisation status

Authorised (453) Apply Authorised filter Refused (18) Apply Refused filter Withdrawn (66) Apply Withdrawn filter

ATC code

Species

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Opinion status

Negative (2) Apply Negative filter Positive (18) Apply Positive filter

Application type

Initial authorisation (18) Apply Initial authorisation filter Post-authorisation (2) Apply Post-authorisation filter

Withdrawal type

Initial authorisation (68) Apply Initial authorisation filter Post-authorisation (2) Apply Post-authorisation filter

Withdrawal date

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (7) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (62) Apply PM: decision on the application for modification of an agreed PIP filter W: decision granting a waiver in all age groups for all conditions or indications (11) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (12) Apply Yes filter

Compliance procedure number

Orphan designation – intended use

Orphan decision number

Orphan designation status

Positive (231) Apply Positive filter Withdrawn (6) Apply Withdrawn filter

Medicine type

Biosimilar Remove Biosimilar filter Generic Remove Generic filter Orphan medicine Remove Orphan medicine filter Accelerated assessment (113) Apply Accelerated assessment filter Additional monitoring (677) Apply Additional monitoring filter Conditional approval (110) Apply Conditional approval filter Exceptional circumstances (77) Apply Exceptional circumstances filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

945 results

Remove all filtersRemove all filters

Categories Human Remove Human filter Veterinary Remove Veterinary filter

Medicine type Generic Remove Generic filter Orphan medicine Remove Orphan medicine filter Biosimilar Remove Biosimilar filter

Medicine Summaries of opinion Remove Summaries of opinion filter Orphan designations Remove Orphan designations filter European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Withdrawn applications Remove Withdrawn applications filter

Sort by

List item

Human medicine European public assessment report (EPAR): Oyavas (updated)

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 26/03/2021, , , Revision: 3, Authorised, Last updated: 05/07/2022
List item

Human medicine European public assessment report (EPAR): Imatinib Actavis (updated)

imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Myelodysplastic-Myeloproliferative Diseases; Hypereosinophilic Syndrome; Dermatofibrosarcoma
Date of authorisation: 17/04/2013, , Revision: 13, Withdrawn, Last updated: 05/07/2022
List item

Human medicine European public assessment report (EPAR): Vizarsin (updated)

sildenafil, Erectile Dysfunction
Date of authorisation: 21/09/2009, , Revision: 18, Authorised, Last updated: 04/07/2022
List item

Human medicine European public assessment report (EPAR): Mysildecard (updated)

sildenafil citrate, Hypertension, Pulmonary
Date of authorisation: 15/09/2016, , Revision: 6, Authorised, Last updated: 04/07/2022
List item

Human medicine European public assessment report (EPAR): Sildenafil Teva (updated)

sildenafil, Erectile Dysfunction
Date of authorisation: 30/11/2009, , Revision: 17, Authorised, Last updated: 04/07/2022
List item

Human medicine European public assessment report (EPAR): Filsuvez (updated)

dry extract from birch bark (DER 5-10 : 1), extraction solvent n-heptane 95% (w/w), Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa, Junctional
Date of authorisation: 21/06/2022, , Authorised, Last updated: 04/07/2022
List item

Human medicine European public assessment report (EPAR): Pregabalin Sandoz (updated)

pregabalin, Anxiety Disorders; Neuralgia; Epilepsy
Date of authorisation: 19/06/2015, , Revision: 13, Authorised, Last updated: 01/07/2022
List item

Human medicine European public assessment report (EPAR): Levetiracetam Actavis (updated)

levetiracetam, Epilepsy
Date of authorisation: 03/10/2011, , Revision: 18, Authorised, Last updated: 01/07/2022
List item

Human medicine European public assessment report (EPAR): Pregabalin Sandoz GmbH (updated)

pregabalin, Anxiety Disorders; Epilepsy
Date of authorisation: 19/06/2015, , Revision: 12, Authorised, Last updated: 01/07/2022
List item

Human medicine European public assessment report (EPAR): Rydapt (updated)

Midostaurin, Leukemia, Myeloid, Acute; Mastocytosis
Date of authorisation: 18/09/2017, , Revision: 8, Authorised, Last updated: 01/07/2022
List item

Human medicine European public assessment report (EPAR): Clopidogrel Taw Pharma (previously Clopidogrel Mylan) (updated)

clopidogrel hydrochloride, Peripheral Vascular Diseases; Stroke; Myocardial Infarction; Acute Coronary Syndrome
Date of authorisation: 21/09/2009, , Revision: 20, Authorised, Last updated: 01/07/2022
List item

Human medicine European public assessment report (EPAR): Levetiracetam Actavis Group (updated)

levetiracetam, Epilepsy
Date of authorisation: 04/12/2011, , Revision: 16, Authorised, Last updated: 01/07/2022
List item

Human medicine European public assessment report (EPAR): Xermelo (updated)

telotristat etiprate, Carcinoid Tumor; Neuroendocrine Tumors
Date of authorisation: 17/09/2017, , Revision: 13, Authorised, Last updated: 01/07/2022
List item

Human medicine European public assessment report (EPAR): Inhixa (updated)

enoxaparin sodium, Venous Thromboembolism
Date of authorisation: 15/09/2016, , Revision: 21, Authorised, Last updated: 01/07/2022
List item

Human medicine European public assessment report (EPAR): Abiraterone Mylan (updated)

abiraterone acetate, Prostatic Neoplasms
Date of authorisation: 20/08/2021, , Revision: 2, Authorised, Last updated: 30/06/2022
List item

Human medicine European public assessment report (EPAR): Tadalafil Mylan (updated)

tadalafil, Erectile Dysfunction
Date of authorisation: 21/11/2014, , Revision: 14, Authorised, Last updated: 30/06/2022
List item

Human medicine European public assessment report (EPAR): Memantine ratiopharm (updated)

memantine hydrochloride, Alzheimer Disease
Date of authorisation: 12/06/2013, , Revision: 8, Authorised, Last updated: 30/06/2022
List item

Human medicine European public assessment report (EPAR): Ocaliva (updated)

Obeticholic acid, Liver Cirrhosis, Biliary
Date of authorisation: 12/12/2016, , , , Revision: 13, Authorised, Last updated: 30/06/2022
List item

Human medicine European public assessment report (EPAR): Ambrisentan Mylan (updated)

ambrisentan, Hypertension, Pulmonary
Date of authorisation: 20/06/2019, , Revision: 3, Authorised, Last updated: 29/06/2022
List item

Human medicine European public assessment report (EPAR): Opsumit (updated)

Macitentan, Hypertension, Pulmonary
Date of authorisation: 20/12/2013, , Revision: 20, Authorised, Last updated: 29/06/2022
List item

Human medicine European public assessment report (EPAR): Bemfola (updated)

follitropin alfa, Anovulation
Date of authorisation: 26/03/2014, , Revision: 9, Authorised, Last updated: 28/06/2022
List item

Human medicine European public assessment report (EPAR): Prasugrel Mylan (updated)

prasugrel besilate, Myocardial Infarction; Acute Coronary Syndrome; Angina, Unstable
Date of authorisation: 15/05/2018, , Revision: 8, Authorised, Last updated: 28/06/2022
List item

Human medicine European public assessment report (EPAR): Sildenafil Actavis (updated)

sildenafil, Erectile Dysfunction
Date of authorisation: 10/12/2009, , Revision: 15, Authorised, Last updated: 28/06/2022
List item

Human medicine European public assessment report (EPAR): Votubia (updated)

everolimus, Tuberous Sclerosis
Date of authorisation: 02/09/2011, , Revision: 30, Authorised, Last updated: 27/06/2022
List item

Human medicine European public assessment report (EPAR): Mycophenolate mofetil Teva (updated)

mycophenolate mofetil, Graft Rejection
Date of authorisation: 21/02/2008, , Revision: 25, Authorised, Last updated: 24/06/2022

Load more

945 results

Human medicine European public assessment report (EPAR): Oyavas (updated)

Human medicine European public assessment report (EPAR): Imatinib Actavis (updated)

Human medicine European public assessment report (EPAR): Vizarsin (updated)

Human medicine European public assessment report (EPAR): Mysildecard (updated)

Human medicine European public assessment report (EPAR): Sildenafil Teva (updated)

Human medicine European public assessment report (EPAR): Filsuvez (updated)

Human medicine European public assessment report (EPAR): Pregabalin Sandoz (updated)

Human medicine European public assessment report (EPAR): Levetiracetam Actavis (updated)

Human medicine European public assessment report (EPAR): Pregabalin Sandoz GmbH (updated)

Human medicine European public assessment report (EPAR): Rydapt (updated)

Human medicine European public assessment report (EPAR): Clopidogrel Taw Pharma (previously Clopidogrel Mylan) (updated)

Human medicine European public assessment report (EPAR): Levetiracetam Actavis Group (updated)

Human medicine European public assessment report (EPAR): Xermelo (updated)

Human medicine European public assessment report (EPAR): Inhixa (updated)

Human medicine European public assessment report (EPAR): Abiraterone Mylan (updated)

Human medicine European public assessment report (EPAR): Tadalafil Mylan (updated)

Human medicine European public assessment report (EPAR): Memantine ratiopharm (updated)

Human medicine European public assessment report (EPAR): Ocaliva (updated)

Human medicine European public assessment report (EPAR): Ambrisentan Mylan (updated)

Human medicine European public assessment report (EPAR): Opsumit (updated)

Human medicine European public assessment report (EPAR): Bemfola (updated)

Human medicine European public assessment report (EPAR): Prasugrel Mylan (updated)

Human medicine European public assessment report (EPAR): Sildenafil Actavis (updated)

Human medicine European public assessment report (EPAR): Votubia (updated)

Human medicine European public assessment report (EPAR): Mycophenolate mofetil Teva (updated)